{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:08:09Z","timestamp":1787497689952,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Palbociclib is a selective well-tolerated antineoplastic drug used in the treatment of advanced HER2-negative, estrogen-receptor positive breast cancer that has shown significant improvement in progression-free survival. We present a patient that developed severe rhabdomyolysis with tetra-affection and loss of gait after initiating the first cycle of Palbociclib concomitantly with Simvastatin 40\u2009mg treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 71-year-old woman with metastatic breast cancer developed tetraparesis and near fatal rhabdomyolysis after initiation of first cycle Palbociclib. For 10 years prior to this treatment, the patient had been treated with Simvastatin without myalgia or other neuromuscular complaints prior to the first cycle of Palbociclib. The patient was admitted at the neurology department, where Palbociclib and Simvastatin were discontinued. The patient was aggressively hydrated and treated with intravenous immunoglobulin therapy with slowly remission and finally regaining independent gait function. Evaluation showed a negative myositis antibody work-up. Muscle magnetic resonance imaging showed edema in multiple foci, but skeletal muscle biopsy did not show necrosis. Post discharge genetic analysis showed single heterozygosity for nucleotide polymorphism\n                      <jats:italic>rs4149056<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      We present a patient who developed severe rhabdomyolysis induced by a combination of Palbociclib and Simvastatin treatment. Rhabdomyolysis was most likely induced by toxic plasma concentrations of Simvastatin due to Palbociclibs inhibition of the CYP3A4 enzyme in combination with a decreased hepatic uptake of Simvastatin due to single nucleotide polymorphism\n                      <jats:italic>rs4149056<\/jats:italic>\n                      . The study underscores that combining Simvastatin and Palbociclib should be done cautiously and genetic testing of the rs4149056 SNP is warranted. If present, Simvastatin should be discontinued or replaced with a lesser myopathic statin in regard to patients risk of cardiovascular events.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-019-1490-4","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T06:48:33Z","timestamp":1571813313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-9626","authenticated-orcid":false,"given":"Vardan","family":"Nersesjan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Duno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina D.","family":"Jeppesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"issue":"5","key":"1490_CR1","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1124\/mol.115.099325","volume":"88","author":"ME Law","year":"2015","unstructured":"Law ME, Corsino PE, Narayan S, Law BK. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics. Mol Pharmacol. 2015 [cited 2019 Feb 5];88(5):846\u201352.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"1490_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 [cited 2019 Feb 5];17(4):425\u201339.","journal-title":"Lancet Oncol"},{"key":"1490_CR3","unstructured":"Updated Data from Phase 3 Trial of IBRANCE\u00ae (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival | Pfizer: One of the world\u2019s premier biopharmaceutical companies. [cited 2019 Feb 5]."},{"issue":"1","key":"1490_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11523-017-0541-2","volume":"13","author":"S Vijayaraghavan","year":"2018","unstructured":"Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in cancer therapy: current evidence and future directions. Target Oncol. 2018 [cited 2019 Feb 5];13(1):21\u201338.","journal-title":"Target Oncol"},{"key":"1490_CR5","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"10","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018 [cited 2019 Feb 5];10:175883591879332.","journal-title":"Ther Adv Med Oncol"},{"key":"1490_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fonc.2017.00150","volume":"7","author":"KL Nelson","year":"2017","unstructured":"Nelson KL, Stenehjem D, Driscoll M, Gilcrease GW. Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib. Front Oncol. 2017 [cited 2019 Feb 5];7:150.","journal-title":"Front Oncol"},{"issue":"1","key":"1490_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.dld.2014.07.170","volume":"47","author":"D Pastori","year":"2015","unstructured":"Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015 [cited 2019 Feb 8];47(1):4\u201311.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"1490_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/bcp.12360","volume":"78","author":"D Mo\u00dfhammer","year":"2014","unstructured":"Mo\u00dfhammer D, Schaeffeler E, Schwab M, M\u00f6rike K. Mechanisms and assessment of statin-related muscular adverse effects. Br J Clin Pharmacol. 2014 [cited 2019 Feb 8];78(3):454\u201366.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1490_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cjca.2010.12.024","volume":"27","author":"A Holbrook","year":"2011","unstructured":"Holbrook A, Wright M, Sung M, Ribic C, Baker S. Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship? Can J Cardiol. 2011 [cited 2019 Feb 8];27(2):146\u201351.","journal-title":"Can J Cardiol"},{"key":"1490_CR10","doi-asserted-by":"crossref","unstructured":"Mantas D, Kostakis JD, Markopoulos C. Aromatase inhibitors: a comprehensive review in mechanisms of action, side effects and treatment in postmenopausal early breast cancer patients. Hell J Surg. 2016;88:245.","DOI":"10.1007\/s13126-016-0326-6"},{"issue":"8","key":"1490_CR11","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.amjcard.2005.12.010","volume":"97","author":"M Law","year":"2006","unstructured":"Law M, Rudnicka AR. Statin Safety: A Systematic Review. Am J Cardiol. 2006 [cited 2019 Feb 5];97(8):S52\u201360.","journal-title":"Am J Cardiol"},{"key":"1490_CR12","volume-title":"IBRANCE- palbociclib capsule","author":"U.S. National Library of Medicine","year":"2016","unstructured":"U.S. National Library of Medicine. IBRANCE- palbociclib capsule. Kirkland: Quebec: Pfizer Canada Inc; 2016. [cited 2019 Feb 9]"},{"key":"1490_CR13","doi-asserted-by":"publisher","unstructured":"Stewart A. SLCO1B1 Polymorphisms and Statin-Induced Myopathy. PLoS Curr. 2013 [cited 2019 Feb 8];5.\u00a0Edition 1. \n                    https:\/\/doi.org\/10.1371\/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203\n                    \n                  .","DOI":"10.1371\/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203"},{"key":"1490_CR14","doi-asserted-by":"crossref","unstructured":"Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011.\u00a0May;21(5):280\u20138.","DOI":"10.1097\/FPC.0b013e328343dd7d"},{"key":"1490_CR15","doi-asserted-by":"crossref","unstructured":"Robertson JFR, Harrison M. Fulvestrant: Pharmacokinetics and pharmacology. Br J Cancer. 2004;90(Suppl 1):S7\u201310.","DOI":"10.1038\/sj.bjc.6601630"},{"key":"1490_CR16","doi-asserted-by":"crossref","unstructured":"Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Therapeutic Advances in Medical Oncology. 2019;11:1758835919833867.","DOI":"10.1177\/1758835919833867"},{"issue":"15_suppl","key":"1490_CR17","doi-asserted-by":"publisher","first-page":"8077","DOI":"10.1200\/jco.2014.32.15_suppl.8077","volume":"32","author":"PK Gopalan","year":"2014","unstructured":"Gopalan PK, Pinder MC, Chiappori A, Ivey AM, Gordillo Villegas A, Kaye FJ. A phase II clinical trial of the CDK 4\/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A. J Clin Oncol. 2014 [cited 2019 Feb 5];32(15_suppl):8077.","journal-title":"J Clin Oncol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1490-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1490-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1490-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T19:08:21Z","timestamp":1603220901000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1490-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1490-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"4 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Consent for use of data obtained from patient, and copy is available upon request.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for on written form obtained from patient, and copy is available upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"247"}}